#78. From Too Few to Too Many

<p>AI can now generate millions of molecules, thousands of drug targets, and entire scientific manuscripts in hours — but our capacity to validate any of it hasn&#39;t kept pace. This episode walks through the trust crisis in AI drug discovery: from ultra-large virtual screening libraries to AI-generated papers arriving faster than peer review can handle, from citation errors in machine-written manuscripts to the clinical programs that give real reason for optimism. The central question is no longer whether AI can generate drug candidates, but whether it can reliably improve therapeutic decisions — and why trustworthy evidence must become the industry&#39;s most valuable asset. Produced by Dr. Jake Chen.</p>